How to Get Dayvigo (Lemborexant) in South Carolina

What Is Dayvigo and Why It Works Differently From Older Sleep Aids

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) that received FDA approval in December 2019 for the treatment of insomnia in adults [1]. Unlike benzodiazepines or Z-drugs such as zolpidem, lemborexant does not globally suppress central nervous system activity. Instead, it blocks orexin-A and orexin-B from binding to OX1R and OX2R receptors, which are the wake-promoting circuits that must be "turned off" for normal sleep onset [2].

The distinction matters clinically. In SUNRISE-1 (N=1,992), published in JAMA Network Open, lemborexant 5 mg and 10 mg both produced statistically significant reductions in subjective sleep onset latency versus zolpidem extended-release 6.25 mg and placebo at month 6, with 10 mg achieving a mean reduction of 20.5 minutes from baseline (P<0.001) [1]. Residual morning sedation scores on the Karolinska Sleepiness Scale were numerically lower for lemborexant 10 mg than for zolpidem ER 6.25 mg at the same time point [1].

The FDA label permits dosing at 5 mg initially, with a clinician-authorized increase to 10 mg if the lower dose is tolerated but insufficiently effective [3]. Patients with moderate hepatic impairment should not exceed 5 mg. The drug is Schedule V under the Controlled Substances Act, meaning it requires a written or electronic prescription from a DEA-registered prescriber and cannot be called in by phone in many pharmacy workflows [3].

South Carolina Telehealth Rules and Who Can Prescribe Dayvigo

South Carolina permits telehealth prescribing of Schedule V controlled substances, provided the prescriber holds an active South Carolina medical license and a DEA registration valid in the state [4]. Physicians (MD/DO), nurse practitioners with prescriptive authority, and physician assistants with supervising-physician agreements are all authorized to prescribe lemborexant in South Carolina under the South Carolina Pharmacy Practice Act and the state's telehealth parity statute [4].

A full synchronous audio-video visit satisfies the "valid patient-physician relationship" standard under South Carolina law. Asynchronous-only (store-and-forward) encounters are generally not sufficient to establish a new controlled-substance relationship for a Schedule V medication, though they may support follow-up refills once the relationship is established.

For telehealth specifically, the prescriber must document the patient's identity, chief complaint, relevant medical history, and a clinical rationale for lemborexant over non-pharmacologic options (such as cognitive behavioral therapy for insomnia, CBT-I, which the American Academy of Sleep Medicine still lists as first-line) [5]. The American College of Physicians 2016 guideline similarly recommends CBT-I as the initial treatment for chronic insomnia disorder [6]. Prescribers who skip this documentation step face prior-authorization denials and potential board scrutiny.

Step-by-Step: How to Get a Dayvigo Prescription in South Carolina

Getting lemborexant in South Carolina follows a predictable sequence. Each step has a realistic time estimate.

Step 1. Choose a provider (Day 1) Book a telehealth appointment with a HealthRX-affiliated clinician or an in-state sleep medicine specialist. Confirm the provider holds a South Carolina medical license and DEA registration. Most telehealth platforms schedule new-patient sleep appointments within 24 to 72 hours.

Step 2. Complete intake and baseline documentation (Day 1 to 2) Upload or self-report your sleep history, any prior insomnia treatments, alcohol and substance use, and a list of current medications. Lemborexant has a clinically meaningful interaction with moderate-to-strong CYP3A inhibitors (for example, fluconazole), which can increase lemborexant exposure by up to 4-fold [3]. Strong CYP3A inducers such as rifampin reduce exposure substantially and may render the drug ineffective [3].

Step 3. Synchronous video visit (Day 2 to 3) During the visit, your provider assesses sleep onset latency, sleep maintenance, daytime impairment, and rules out secondary causes such as obstructive sleep apnea or restless leg syndrome. No specific laboratory tests are required by the FDA label before initiating lemborexant, though a metabolic panel is reasonable if hepatic impairment is suspected [3].

Step 4. Prescription transmission (Day 3) The provider sends an electronic prescription to your preferred South Carolina pharmacy. Because lemborexant is Schedule V, most pharmacies require an e-prescription or a written hard-copy. Verbal orders are not standard for Schedule V in most pharmacy workflows, though state law does not explicitly prohibit them for Schedule V as it does for Schedule II through IV.

Step 5. Prior authorization (Day 3 to 6) Most commercial insurers in South Carolina require prior authorization (PA) for Dayvigo. The PA process is covered in its own section below. Budget 2 to 5 business days for standard PA review.

Step 6. Dispensing and pickup or delivery (Day 5 to 7) Once PA is approved, the pharmacy dispenses the drug. Retail pharmacies in major South Carolina cities (Columbia, Charleston, Greenville, Myrtle Beach) stock Dayvigo or can order it within 24 hours. Mail-order pharmacy delivery typically takes 2 to 4 business days from the date of PA approval.

What Labs Are Needed Before Starting Dayvigo in South Carolina

The FDA label for lemborexant does not mandate specific laboratory testing before initiation [3]. In practice, providers commonly order the following:

A comprehensive metabolic panel (CMP) checks liver function (AST, ALT, bilirubin, alkaline phosphatase) because lemborexant is hepatically metabolized via CYP3A4. Patients with moderate hepatic impairment (Child-Pugh B) must stay at or below 5 mg [3]. Patients with severe hepatic impairment (Child-Pugh C) should not use the drug at all [3].

A urine drug screen may be ordered to identify concurrent CNS depressant use (opioids, benzodiazepines, other sedative-hypnotics) that could compound respiratory depression risk during sleep.

A standardized sleep questionnaire such as the Insomnia Severity Index (ISI) or Pittsburgh Sleep Quality Index (PSQI) is not a lab test but is standard documentation that supports medical necessity for PA purposes. An ISI score of 15 or above (moderate-to-severe insomnia) is commonly cited in PA submissions.

If obstructive sleep apnea has not been ruled out, the STOP-BANG questionnaire or an at-home sleep apnea test may be ordered before or concurrent with lemborexant initiation, since the drug suppresses arousal responses [2].

Prior Authorization Requirements in South Carolina

Prior authorization is the single most common delay South Carolina patients encounter. Most major commercial plans covering medications through a PBM (pharmacy benefit manager) classify Dayvigo as a non-preferred brand on a 3- or 4-tier formulary, triggering automatic PA review [7].

The following framework reflects the documentation elements that South Carolina commercial PA submissions for lemborexant typically require:

1. Diagnosis with ICD-10 code. G47.00 (insomnia, unspecified) or G47.09 (other insomnia) with documented duration of at least 3 months, consistent with the DSM-5 and ICSD-3 chronic insomnia criteria.

2. Failure of generic alternatives. Most plans require documented trials of at least one generic first-line agent. Zolpidem (generic) and trazodone (off-label, generic) are the two most commonly required step-therapy drugs. Document the drug name, dose, trial duration, and reason for discontinuation or inadequate response.

3. CBT-I attempt or contraindication. As the American Academy of Sleep Medicine guideline notes, CBT-I is the preferred first-line treatment for chronic insomnia disorder [5]. The PA form often asks whether CBT-I was offered and, if the patient declined or lacked access, a clinical rationale must be provided.

4. Clinical notes from the visit. A brief office note or telehealth visit summary that documents sleep onset latency, wake after sleep onset, total sleep time, and functional impairment strengthens the submission.

5. Prescriber attestation. Some SC plans require the prescriber to attest that the patient is not using other CNS depressants that would contraindicate a new DORA prescription.

Turnaround for standard PA is 2 to 5 business days in South Carolina under state prompt-pay rules. Urgent PA (when the insurer accepts that criterion) must be answered within 72 hours. If denied, South Carolina law provides for an internal appeal and then an independent external review through the South Carolina Department of Insurance [8].

SC Medicaid and Commercial Insurance Coverage

South Carolina Medicaid (Healthy Connections) does not cover Dayvigo as of the 2025 formulary [9]. Patients enrolled in SC Medicaid who need pharmacologic insomnia treatment are generally directed to generic doxepin 3 mg or 6 mg (Silenor generic), trazodone, or zolpidem on the preferred drug list.

Commercial insurance coverage in South Carolina varies by plan and employer contract. Plans using Express Scripts or CVS Caremark PBMs have historically placed Dayvigo on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with copays ranging from $40 to $120 per 30-day supply after PA approval. Eisai maintains a savings card program for commercially insured patients that may reduce out-of-pocket cost to as low as $0 for eligible fills; patients can enroll at the manufacturer's website.

Cash-pay pricing at major South Carolina retail pharmacies averages $360 to $420 for a 30-day supply of Dayvigo 10 mg without insurance or manufacturer assistance. GoodRx and similar discount programs may reduce this to $280 to $330 depending on the pharmacy location.

503A Compounding Pharmacies in South Carolina

South Carolina-licensed 503A compounding pharmacies may prepare lemborexant formulations for an individual patient when a valid prescription is received from a licensed practitioner [10]. A 503A pharmacy compounds for specific patients one at a time. It does not manufacture bulk stock for general distribution, which distinguishes it from a 503B outsourcing facility [10].

Compounded lemborexant is not bioequivalent to FDA-approved Dayvigo, and compounding is not subject to FDA's new drug approval process. Patients and prescribers should understand that compounded preparations lack the clinical trial data supporting the approved formulation. The FDA has not placed lemborexant on the drug shortage list as of 2025, so the legal basis for compounding a commercially available drug should be reviewed with the compounding pharmacist and prescriber [10].

For patients who cannot afford brand Dayvigo and do not qualify for the manufacturer savings card, a compounding consultation is worth discussing with your provider. The prescriber must write the prescription specifically for a compounded form, naming the active ingredient, dose, and dosage form. The 503A pharmacy in South Carolina must be licensed by the South Carolina Board of Pharmacy.

Transferring an Existing Dayvigo Prescription to South Carolina

Patients relocating to South Carolina from another state sometimes ask whether they can transfer their existing Dayvigo prescription. The practical answer is nuanced.

Schedule V prescriptions may be transferred between pharmacies in South Carolina under federal law, but only once between non-chain pharmacies. Pharmacies within the same chain (for example, CVS to CVS) may allow multiple electronic transfers [11]. The receiving South Carolina pharmacy must confirm that the original prescription was issued by a DEA-registered prescriber and that refills remain.

If the original prescriber is not licensed in South Carolina, the prescription is still valid for a one-time fill or transfer as long as it was lawfully issued in the original state [11]. For ongoing refills, however, the patient will need a South Carolina-licensed prescriber to write new prescriptions once the original supply is exhausted. A telehealth provider licensed in South Carolina can typically complete this handoff in one visit.

Dayvigo Dosing, Safety, and What to Expect Clinically

Lemborexant is taken once per night, within 30 minutes of going to bed, with at least 7 hours remaining before planned awakening [3]. The starting dose is 5 mg. If 5 mg is tolerated but sleep onset or maintenance remains inadequate, the prescriber may increase to 10 mg [3].

In SUNRISE-2 (N=949), a 12-month placebo-controlled trial, lemborexant maintained efficacy on subjective sleep onset latency and wake after sleep onset through 12 months without evidence of rebound insomnia upon discontinuation [12]. The most common adverse event was somnolence, reported in 10% to 12% of patients on 10 mg vs. 1% to 3% on placebo [12].

Driving impairment the morning after a 10 mg dose is a documented concern. A dedicated driving simulation study found that lemborexant 10 mg taken with 8 hours in bed produced mean standard deviation of lateral position (SDLP) scores that were significantly elevated versus placebo at 9 hours post-dose (P<0.05), though the effect was not statistically significant at 11 hours post-dose [13]. The FDA label carries a warning about next-morning impairment, particularly at the 10 mg dose [3].

Patients with a history of sleepwalking, sleep paralysis, or complex sleep behaviors (sleep-driving, sleep-eating) should report these to their prescriber immediately, as the FDA issued a class warning for DORA agents including lemborexant regarding complex sleep behaviors [3].

The drug is not recommended during pregnancy (risk category data are limited) and should be used with caution in breastfeeding given limited data on excretion in human milk [3].

How HealthRX Supports South Carolina Patients

HealthRX clinicians licensed in South Carolina conduct synchronous telehealth visits for insomnia assessment and, when clinically appropriate, prescribe lemborexant. The clinical intake collects ISI scores, sleep diary data, medication history, and CYP3A drug interaction screening before the visit. This preparation shortens the average time from booking to prescription transmission to under 48 hours for most patients.

For patients whose commercial insurance requires PA, the HealthRX care coordination team submits the PA documentation, monitors status, and initiates appeals if the first submission is denied. For patients on SC Medicaid or without insurance, the team reviews eligibility for Eisai's patient assistance program and, if indicated, provides a referral to a South Carolina-licensed 503A compounding pharmacy.